Novel approaches with targeted therapies in bladder cancer: Therapy of bladder cancer by blockade of the epidermal growth factor receptor family
Introduction
Transitional cell carcinoma of the bladder (TCC) is the fifth most common solid malignancy in the United States. It is diagnosed in approximately 54,000 patients and results in 12,000 deaths annually [1]. The standard treatment for operable invasive bladder cancer is radical cystectomy. Patients with metastatic TCC are usually treated with systemic chemotherapy [2], [3], [4], [5]. For more than a decade, the standard treatment for metastatic urothelial cancer has been combination therapy with methotrexate, vinblastine, adriamycin and cisplatin (MVAC). This regimen is consistently reported to produce a median survival in the range of 13–15 months [3], [4]. Despite considerable effort to dose-escalate or otherwise modulate the components of M-VAC [6], no improvement in survival has been observed. In the search for regimens more active than M-VAC, regimens based on gemcitabine, ifosfamide, and/or paclitaxel have attracted considerable interest [7], [8], [9], [10]. Although high response rates have been reported using these new agents in combination, a recent randomized trial of the combination of gemcitabine and cisplatin (GC) versus MVAC failed to demonstrate an improved survival with the doublet. However, GC had an improved toxicity profile [11].
The desire to improve outcome utilizing new active agents led to the development of a phase I/II trial testing the combination of paclitaxel, cisplatin, and gemcitabine [12]. The study gave an overall response rate of 78% and a median survival time for the phase II part of the study of 15.8 months. Based upon the favorable results obtained with this triplet, the EORTC, the Southwest Oncology Group (SWOG), National Cancer Institute of Canada (NCIC), the Radiation Therapy Oncology Group (RTOG), the Spanish Oncology Genito-Urinary Group (SOGUG) and several other collaborative groups have begun a randomized trial to compare the three drug regimen of paclitaxel–cisplatin–gemcitabine with the two-drug combination of GC. Similarly, investigators at Wayne State University conducted a phase II trial incorporating gemcitabine into the carboplatin, paclitaxel combination in previously untreated patients with advanced urothelial malignancy with also encouraging results. The median response rate was 68% with a median survival of 14.7 months [13]. However, to date there are no compelling data that survival could be definitively improved with the triplet regimens and the role of triplet therapy awaits outcome from ongoing randomized trials.
Currently, there is a growing conviction that the cytotoxic paradigm, as we have known it, will not provide the means to qualitatively change the outcome for patients with metastatic bladder cancer. Hence, the importance of developing novel therapeutic approaches. Although, relatively little is known about the biological markers governing advanced bladder cancer response to treatment, it is especially important to identify these cellular and molecular alterations, as well as the manner in which they influence host–tumor interactions since gaining such knowledge is essential for the design of more effective future therapies.
Section snippets
Targeted treatments in urologic malignancies
Cells must acquire a series of traits in order to become malignant and to develop advanced lethal cancers. These traits have been elegantly grouped in the following categories: growth factor independence; insensitivity to antiproliferative signals; escape from apoptosis; unlimited proliferative capacity; angiogenesis; and ability for invasion and metastasis. The knowledge of the molecular pathways that underlie each of these traits is critical to improve the treatment of cancer at least from
Biological role of EGF receptor family in malignancy
EGF receptor and HER2 are plasma membrane glycoproteins that belong to the EGF receptor family (also known as type I receptor tyrosine kinases (TKs) or ErbB TK receptors). This receptor family is comprised of four closely related receptors: the EGF receptor itself (ErbB1/EGFr/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). Since the EGF receptor was the first one identified, this receptor family is also collectively described as the EGF receptor family. These receptors are composed of
McAb against EGF receptor
The demonstration that anti-EGF receptor monoclonal antibodies inhibited the growth of cancer cells expressing the EGF receptor [39], [40], [41], [42] lead to a series of clinical trials with anti-EGF receptor monoclonal antibodies in patients with EGF receptor positive tumors.
Of a series of anti-EGFR monoclonal antibodies under clinical development, IMC-C225 (Cetuximab™), is the one in a more advanced phase in clinical development, with particularly promising results. Cetuximab is a
Conclusions
The findings observed with different agents and in different tumor types validate EGFR and Her-2 as useful targets for cancer therapy. Preclinical studies in bladder cancer models, confirm that systemic administration of EGFR inhibitors inhibits the growth and metastasis of human TCC established in the bladder wall of athymic nude mice. Therapy with these agents has a significant antitumor effect mediated, in part, by inhibition of angiogenesis and invasion. The downregulation of angiogenic
Reviewers
Professor Hans von der Maase, Professor of Oncology, Department of Oncology, Aarhus University Hospital, DK-8000 Aarhus, Denmark.
Ronald de Wit, MD, PhD, Medical Oncologist, Erasmus Medical Center, Groene Hilledijk 301, Room G4-82, Postbus 5201, NL-3075 EA Rotterdam, The Netherlands.
Joaquim Bellmunt MD, Genitourinary Oncology at Vall d'Hebron University Hospital. Autónoma University of Barcelona. Barcelona. Consultant of the Chemotherapy Committee of the EORTC Genito-Urinary Group. EORTC-30987 Study Chairman. EORTC-30986 Study Co-Coordinator.
References (207)
- et al.
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium
J. Urol.
(1988) - et al.
Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification
J. Urol.
(1991) - et al.
The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer
Pathol. Res. Pract.
(1997) - et al.
Regulation of signal transduction and signal diversity by receptor oligomerization
TIBS
(1994) - et al.
Signal transduction through MAP kinase cascades
Adv. Cancer Res.
(1998) - et al.
Heregulin regulation of Akt/protein kinase B in breast cancer cells
Biochem. Biophys. Res. Commun.
(1999) - et al.
Epidermal growth factor-related peptides and their receptors in human malignancies
Crit. Rev. Oncol. Hematol.
(1995) - et al.
Reduced growth rate accompanied by aberrant epidermal growth factor signalling in drug resistant human breast cancer cells
Biochim. Biophys. Acta
(2000) - et al.
The Wilet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy
J. Urol.
(2001) - et al.
Angiogenesis
J. Biol. Chem.
(1992)
Tumor interactions with the vasculature: angiogenesis and tumor metastasis
Biochim. Biophys. Acta
Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine
J. Urol.
Transforming growth factors-B1 and B2 in serum and urine from patients with bladder carcinoma
J. Urol.
Both ν-Ha-Ras and ν-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
J. Biol. Chem.
Radical prostatectomy after definitive radiation therapy for prostate cancer
Urology
basic fibroblast growth factor regulates matrix metalloprotease production and in vitro invasiveness in human bladder cancer cell lines
J. Urol.
MMP-9/gelatinse B is a key regulator of growth pate angiogenesis and apoptosis of hypertrophic chondrocytes
Cell
Cancer statistics
CA Cancer J. Clin.
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
Cancer
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
Cancer
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for initial treatment of advanced malignant urothelial tumors: results of a randomized trial
J. Clin. Oncol.
Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol.
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen
J. Clin. Oncol.
Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
J. Clin. Oncol.
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial
J. Clin. Oncol.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study
J. Clin. Oncol.
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
J. Clin. Oncol.
Combination carboplatin, paclitaxel and gemcitabine. Is an active teatment for advanced urothelial carcinoma
J. Clin. Oncol.
Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
Br. J. Cancer
Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder
Clin. Cancer Res.
Signal transduction. Look at a tyrosine kinase
Nature
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand–receptor interactions
FEBS Lett.
Specificity within the EGF family/erbB receptor family signaling network
Bioassays
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Nature
Controlled dimerization of erbB receptors provides evidence for differential signalling by homo- and heterodimers
Mol. Cell. Biol.
AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation
Annu. Rev. Biochem.
Oncogenic kinase signalling
Nature
Immunohistochemical markers in the morphological diagnosis of lung carcinoma
Rom. J. Morphol. Embryol.
The epidermal growth factor receptor in breast cancer
J. Mammary Gland Biol. Neoplasia
Differential expression of epidermal growth factor receptor in human head and neck cancers
Head Neck
The epidermal growth factor receptor (EGFR): A new target in cancer therapy
Signal
Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas
Invasion Metastasis
Antiapoptotic signalling by the insulin-like growth factor 1 receptor, phosphatidylinositol 3-kinase and Akt
Mol. Cell. Biol.
Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
Anticancer Res.
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
Clin. Cancer Res.
Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
Proc. Natl. Acad. Sci. USA
Biological effect in vitro of monoclonal antibodies to human EGF receptors
Mol. Biol. Med.
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects
Cancer Res.
Cited by (0)
Joaquim Bellmunt MD, Genitourinary Oncology at Vall d'Hebron University Hospital. Autónoma University of Barcelona. Barcelona. Consultant of the Chemotherapy Committee of the EORTC Genito-Urinary Group. EORTC-30987 Study Chairman. EORTC-30986 Study Co-Coordinator.
Maha Hussain MD, FACP, Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center. Dr. Hussain is a fellow of the American College of Physicians, member of American Society of Clinical Oncology, serves as the chair for Advanced Prostate Cancer Subcommittee of the SWOG.
Colin P Dinney MD, Professor of Urology at The University of Texas M. D. Anderson Cancer Center. Dr. Dinney is the PI of the M. D. Anderson GU SPORE in Bladder Cancer Research.